IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis

Deepak Balak; Martijn van Doorn; RD Arbeit; R Rijneveld; E Klaassen; T Sullivan; J Brevard; Bing Thio; Errol Prens; J Burggraaf; R Rissmann

doi:10.1016/j.clim.2016.09.015

IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis

Deepak Balak
, Martijn van Doorn
, RD Arbeit
, R Rijneveld
, E Klaassen
, T Sullivan
, J Brevard
, Bing Thio
, Errol Prens
, J Burggraaf
, R Rissmann

Dermatology

Research output: Contribution to journal › Article › Academic › peer-review

84 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	63-72
Number of pages	10
Journal	Clinical Immunology
Volume	174
DOIs	https://doi.org/10.1016/j.clim.2016.09.015
Publication status	Published - 2016

Research programs

EMC MM-03-61-05-A
EMC OR-01

Access to Document

10.1016/j.clim.2016.09.015

http://hdl.handle.net/1765/94623

Cite this

Balak, D., van Doorn, M., Arbeit, RD., Rijneveld, R., Klaassen, E., Sullivan, T., Brevard, J., Thio, B., Prens, E., Burggraaf, J., & Rissmann, R. (2016). IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. Clinical Immunology, 174, 63-72. https://doi.org/10.1016/j.clim.2016.09.015

@article{9b905c860e7d4f7dae85c4636f41e49a,

title = "IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis",

author = "Deepak Balak and \{van Doorn\}, Martijn and RD Arbeit and R Rijneveld and E Klaassen and T Sullivan and J Brevard and Bing Thio and Errol Prens and J Burggraaf and R Rissmann",

year = "2016",

doi = "10.1016/j.clim.2016.09.015",

language = "Undefined/Unknown",

volume = "174",

pages = "63--72",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press",

}

Balak, D, van Doorn, M, Arbeit, RD, Rijneveld, R, Klaassen, E, Sullivan, T, Brevard, J, Thio, B, Prens, E, Burggraaf, J & Rissmann, R 2016, 'IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis', Clinical Immunology, vol. 174, pp. 63-72. https://doi.org/10.1016/j.clim.2016.09.015

IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. / Balak, Deepak; van Doorn, Martijn; Arbeit, RD et al.
In: Clinical Immunology, Vol. 174, 2016, p. 63-72.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis

AU - Balak, Deepak

AU - van Doorn, Martijn

AU - Arbeit, RD

AU - Rijneveld, R

AU - Klaassen, E

AU - Sullivan, T

AU - Brevard, J

AU - Thio, Bing

AU - Prens, Errol

AU - Burggraaf, J

AU - Rissmann, R

PY - 2016

Y1 - 2016

U2 - 10.1016/j.clim.2016.09.015

DO - 10.1016/j.clim.2016.09.015

M3 - Article

C2 - 27876460

SN - 1521-6616

VL - 174

SP - 63

EP - 72

JO - Clinical Immunology

JF - Clinical Immunology

ER -